Cardiff Oncology reported major leadership changes and a clinical program update. On January 27, 2026, longtime CEO Dr. Mark Erlander and CFO James Levine stepped down as part of a strategic leadership review. The Board appointed director Dr. Mani Mohindru as interim CEO and promoted Brigitte Lindsay, previously Senior Vice President, Finance, to Chief Accounting Officer.
The company also highlighted a positive update from CRDF-004, a randomized Phase 2 trial of its drug candidate onvansertib combined with standard-of-care regimens in first-line RAS‑mutated metastatic colorectal cancer. Details of the results are provided in an attached press release, which is largely incorporated by reference into this report.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.